Abiopharma

JONES LANG LASALLE INC (JLL) Reports the reporting period Financial Results JONES LANG LASALLE INC (JLL) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 1
• Net Income: 47
• EPS: 3.43
• Cash and equivalents: $5,065
  • anticipated in forward-looking statements, and risks to JLL's business in general, please refer to those factors discussed under "Risk Factors," "Business," "Management’s Discussion and Analysis of Financial Condition and Results of Operations," "Quantitative and Qualitative Disclosures about Market Risk," and elsewhere in JLL's Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this release, and except to the extent required by applicable securities laws, JLL expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in expectations or results, new information, developments or any change in events.-continued-JONES LANG LASALLE INCORPORATEDConsolidated Statements of Operations (Unaudited)Three Months Ended March 31,(in millions, except share and per share data)2026